新华医疗(600587) - 2024 Q1 - 季度财报
SHINVASHINVA(SH:600587)2024-04-29 10:07

Financial Performance - Total revenue for Q1 2024 was CNY 2,528,538,840.43, representing a year-on-year increase of 3.68%[14] - Net profit attributable to shareholders for Q1 2024 was CNY 211,036,820.12, an increase of 7.39% compared to the same period last year[14] - Net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 208,965,933.49, reflecting a 13.77% increase year-on-year[14] - Basic and diluted earnings per share for Q1 2024 were both CNY 0.45, a decrease of 2.17% compared to the previous year[14] - The weighted average return on equity was 2.87%, down by 0.45 percentage points from the previous year[14] - Net profit rose to ¥215,024,150.02, compared to ¥202,032,967.27, marking an increase of approximately 6.9%[48] - Total profit amounted to ¥240,004,730.67, up from ¥236,108,942.41, indicating a growth of about 1.9%[47] - The company’s total comprehensive income reached ¥215,024,150.02, compared to ¥202,032,967.27, reflecting an increase of about 6.4%[48] Assets and Liabilities - The total assets at the end of the reporting period were CNY 15,446,957,749.70, a decrease of 0.92% from the end of the previous year[11] - Total assets decreased from 15,590,329,775.23 to 15,446,957,749.70, a decline of approximately 0.92%[43] - Total liabilities decreased from 7,870,494,104.65 to 7,581,952,161.40, a decline of approximately 3.67%[44] - Total equity increased from 7,719,835,670.58 to 7,865,005,588.30, an increase of approximately 1.89%[45] Cash Flow - The net cash flow from operating activities for Q1 2024 was CNY -213,902,750.72, a significant decrease of 1,425.74% year-on-year[14] - Cash flow from operating activities in Q1 2024 was ¥2,244,699,365.87, compared to ¥2,677,674,550.70 in Q1 2023, indicating a decrease of 16.2%[37] - Cash flow from operating activities showed a net outflow of ¥213,902,750.72, contrasting with a net inflow of ¥16,134,620.03 in the previous period[50] - Investment activities resulted in a net cash outflow of ¥85,696,029.09, improving from a larger outflow of ¥139,927,754.81 previously[50] Expenses - Total operating costs for Q1 2024 were ¥2,298,905,534.93, up from ¥2,215,993,908.16 in Q1 2023, reflecting a year-over-year increase of 3.7%[33] - The company’s management expenses decreased to ¥88,190,919.48 in Q1 2024 from ¥113,528,277.78 in Q1 2023, a reduction of 22.3%[33] - Tax expenses for Q1 2024 were reported at ¥14,318,968.54, slightly down from ¥14,661,765.48 in Q1 2023[33] - R&D expenses increased to ¥83,305,119.71 from ¥73,557,725.07, reflecting a growth of approximately 13.7% year-over-year[47] - Financial expenses decreased significantly to ¥4,405,363.44 from ¥8,362,979.58, a reduction of about 47.3%[47] Investments and Other Financial Metrics - The company reported a significant increase in investment income to ¥18,623,683.78 from ¥11,029,530.70, a growth of approximately 68.5%[47] - The company reported a net profit of ¥0 from the merged entity prior to the merger, consistent with the previous period[36] - The company has not indicated any new product launches or technological developments during this reporting period[40] - There were no significant market expansions or acquisitions reported in the current quarter[40] Shareholder Information - The company has maintained a stable shareholder structure, with the largest shareholder holding 28.91% of the shares[26]